Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine

Chantal Pauli, Benjamin D. Hopkins, Davide Prandi, +26

Cancer Discovery

Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas

Franz X. Schaub, Varsha Dhankani, Ashton C. Berger, +720

Cell Systems

Patient derived organoids to model rare prostate cancer phenotypes

Loredana Puca, Rohan Bareja, Davide Prandi, +30

Nature Communications

BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer

Goldie Y.L. Lui, Reid Shaw, Franz X. Schaub, +13

EBioMedicine

Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma

Shogo Shigeta, Goldie Y.L. Lui, Reid Shaw, +9

Molecular Cancer Therapeutics

Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer

Chang Xu, Olga Nikolova, Ryan Basom, +16

Clinical Cancer Research

Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in <i>CCDC6-RET</i> –rearranged thyroid cancer

Renuka Raman, Jacques A. Villefranc, Timothy M. Ullmann, +28

The Journal of Experimental Medicine

Stacking Machine Learning Algorithms for Biomarker-Based Preoperative Diagnosis of a Pelvic Mass

Reid Shaw, Anna Lokshin, Michael Craig Miller, +2

Cancers